Bartram Richard 4

What Happened Richard Bartram, Chief Financial Officer of MBX Biosciences (MBX), was granted a total of 85,000 shares on February 2, 2026: 15,000 restricted stock units (RSUs) and 70,000 derivative share awards. Both grants were reported at a $0.00 per-share acquisition price (typical for compensation awards), so no cash was exchanged. These are grants (transaction code A), not open‑market purchases or sales.

Key Details

• Transaction date: 2026-02-02; Form 4 filed 2026-02-03 (timely filing).
• Grants: 15,000 RSUs (F1) and 70,000 derivative award (F2); combined = 85,000 shares.
• Reported acquisition price: $0.00 for both grants (no cash paid).
• Vesting: F1 — 15,000 RSUs vest over four years in equal quarterly installments. F2 — the 70,000 derivative award vests in 48 equal monthly installments beginning March 2, 2026.
• Shares owned after the transaction: not specified in the provided filing extract.
• No sale or exercise occurred; these are compensation grants.

Context RSUs and other derivative awards are common executive compensation tools and typically vest over time subject to continued service. Because these are future‑vesting awards (not immediate purchases), they do not represent an immediate market buy or sell and should be viewed as part of Bartram's compensation package rather than an active trading signal.